Bayer plans to build a Cell Culture Technology Center in Berkeley, Calif., investing $150 million in the project. The center will focus on developing biologics, an area where Bayer lags behind the company’s competitors.

Life science incubators and accelerators play a highly significant role in the industry and may be the key for regional growth, a new report shows.

JLL’s life sciences experts anticipate that Big Pharma during 2019 will adopt agile real estate strategies and more entrepreneurial approaches to reinvent R&D and compete with smaller enterprises that are doubling down on product innovation and delivery.

Celltrion Inc. signed an ‘Incubation’ agreement with Emory University in Atlanta to support the research and development of new drug candidates for atherosclerosis.

Copenhagen, Denmark-based Novo Nordisk acquired Bristol, UK-based Ziylo in a deal that could exceed $800 million.

Fresh off its $7 billion acquisition of San Diego-based Impact Biomedicines and its JAK inhibitor program targeting myelofibrosis, Celgene is planning to open a biopharma incubator on its corporate campus in New Jersey.